NASDAQ:XLRN - Acceleron Pharma Stock Price, Price Target & More

$36.99 -0.27 (-0.72 %)
(As of 04/19/2018 11:49 AM ET)
Previous Close$37.26
Today's Range$36.50 - $37.51
52-Week Range$24.37 - $46.93
Volume116,287 shs
Average Volume301,947 shs
Market Capitalization$1.74 billion
P/E Ratio-13.90
Dividend YieldN/A
Beta1.43

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200

Debt

Debt-to-Equity RatioN/A
Current Ratio17.04%
Quick Ratio17.04%

Price-To-Earnings

Trailing P/E Ratio-13.90
Forward P/E Ratio-14.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million
Price / Sales125.57
Cash FlowN/A
Price / CashN/A
Book Value$8.07 per share
Price / Book4.58

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-804.49%
Return on Equity-38.71%
Return on Assets-35.91%

Miscellaneous

Employees139
Outstanding Shares45,760,000

How to Become a New Pot Stock Millionaire

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma (NASDAQ:XLRN) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.02. The biopharmaceutical company earned $3.71 million during the quarter, compared to the consensus estimate of $3.39 million. Acceleron Pharma had a negative return on equity of 38.71% and a negative net margin of 804.49%. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

16 brokerages have issued twelve-month target prices for Acceleron Pharma's stock. Their forecasts range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's stock price to reach $47.7333 in the next twelve months. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. Cann analysts commented, "Acceleron announced today preliminary results from the first two cohorts in Part 1 of the phase II clinical study of ACE-083 in patients with facioscapulohumeral dystrophy (FSHD). Results from the tibialis anterior cohort demonstrated patients treated with ACE-083 generated a mean total muscle volume increase of 12.6%; this was associated with a mean improvement in muscle fat fraction of 5.3%. Results from the biceps brachii cohort of the studyl demonstrated patients treated with ACE-083 generated a mean total muscle volume gain of 13.2%; this was associated with a mean improvement in muscle fat fraction of 0.6%." (1/8/2018)
  • 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
  • Mr. Kevin F. McLaughlin, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 62)
  • Dr. Ravindra Kumar Ph.D., Chief Scientific Officer and Sr. VP (Age 58)
  • Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)

Has Acceleron Pharma been receiving favorable news coverage?

Media coverage about XLRN stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acceleron Pharma earned a coverage optimism score of -0.03 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $36.99.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.74 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (XLRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acceleron Pharma (NASDAQ:XLRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $47.7333, suggesting that the stock has a possible upside of 29.04%. The high price target for XLRN is $63.00 and the low price target for XLRN is $20.00. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.592.61
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.7333$47.7333$45.3333$44.0625
Price Target Upside: 29.04% upside17.54% upside0.76% upside13.68% upside

Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History

Price Target History for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2018Credit Suisse GroupReiterated RatingBuy$55.00HighView Rating Details
3/1/2018CitigroupBoost Price TargetBuy -> Positive$44.00 -> $63.00HighView Rating Details
2/28/2018BarclaysBoost Price TargetOverweight -> Overweight$50.00 -> $54.00HighView Rating Details
2/28/2018HC WainwrightReiterated RatingBuy$62.00HighView Rating Details
2/28/2018Piper JaffrayBoost Price TargetOverweight$53.00HighView Rating Details
2/26/2018JPMorgan ChaseUpgradeNeutral -> Overweight$33.00HighView Rating Details
1/8/2018CannReiterated RatingHoldHighView Rating Details
1/8/2018OppenheimerReiterated RatingHoldMediumView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
9/12/2017UBSReiterated RatingBuy$36.00 -> $50.00HighView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 -> $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform -> Market PerformLowView Rating Details
5/17/2017Goldman SachsInitiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Acceleron Pharma (NASDAQ:XLRN) Earnings History and Estimates Chart

Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.62)($0.62)($0.62)
Q2 20182($0.68)($0.59)($0.64)
Q3 20182($0.55)($0.26)($0.41)
Q4 20182($0.89)($0.49)($0.69)

Acceleron Pharma (NASDAQ XLRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.62)N/AView Earnings Details
2/27/2018Q4 2017($0.60)($0.6180)$3.39 million$3.71 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.67)($0.65)$3.52 million$3.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)$8.00 million$4.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Acceleron Pharma (NASDAQ:XLRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acceleron Pharma (NASDAQ XLRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 88.23%
Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ XLRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018John D QuiselSVPSell1,204$38.40$46,233.60View SEC Filing  
4/3/2018Kevin F MclaughlinCFOSell4,000$38.45$153,800.00View SEC Filing  
4/3/2018Matthew L ShermanEVPSell4,600$38.43$176,778.00View SEC Filing  
3/6/2018Richard F PopsDirectorSell37,500$41.42$1,553,250.0068,750View SEC Filing  
1/12/2018Christopher RovaldiSVPSell11,000$45.00$495,000.0035,701View SEC Filing  
1/4/2018Kevin F MclaughlinCFOSell19,000$42.89$814,910.0045,300View SEC Filing  
1/3/2018Christopher RovaldiSVPSell2,266$42.42$96,123.7252,977View SEC Filing  
1/3/2018Matthew L ShermanEVPSell4,633$42.71$197,875.4377,700View SEC Filing  
1/2/2018Kevin F MclaughlinCFOSell4,000$42.42$169,680.0045,300View SEC Filing  
12/15/2017Jean GeorgeDirectorSell105,122$35.73$3,756,009.061,250View SEC Filing  
9/25/2017Corp /De/ CelgeneMajor ShareholderBuy745,592$37.00$27,586,904.006,118,479View SEC Filing  
9/13/2017John D QuiselSVPSell5,113$38.42$196,441.4657,918View SEC Filing  
9/12/2017Christopher RovaldiSVPSell14,000$38.41$537,740.0028,232View SEC Filing  
9/12/2017Kevin F MclaughlinCFOSell16,000$38.41$614,560.0050,810View SEC Filing  
9/12/2017Matthew L ShermanEVPSell18,400$38.41$706,744.0079,750View SEC Filing  
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65108,392View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.0080,950View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00112,400View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.0096,264View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.0072,200View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.0098,100View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00130,977View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.004,000View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.881,624View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.1291,875View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.6077,004View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.3286,723View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00147,106View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26147,106View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20137,365View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84147,106View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.0082,900View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.0091,500View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08137,365View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00160,674View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.0095,524View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00131,098View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.005,372,887View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.0091,604View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00119,084View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.0080,000View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.0096,404View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.0056,685View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00119,656View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.0076,123View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.0021,584View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.0040,000View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00206,500View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.0027,656View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.004,572,887View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.004,867View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.0045,890View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.0027,656View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acceleron Pharma (NASDAQ XLRN) News Headlines

Source:
DateHeadline
Acceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClubAcceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 19 at 9:23 AM
Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell"Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 18 at 10:23 AM
$4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter$4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - April 18 at 2:46 AM
Acceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per ShareAcceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 16 at 3:14 PM
Acceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment ResearchAcceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:26 PM
Q4 Biotech Catalyst Watchlist: Phase 3 Clinical TrialsQ4 Biotech Catalyst Watchlist: Phase 3 Clinical Trials
seekingalpha.com - April 10 at 8:25 AM
Acceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by BrokeragesAcceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 12:10 PM
Acceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 SharesAcceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 Shares
www.americanbankingnews.com - April 4 at 11:37 PM
Acceleron Pharma (XLRN) EVP Sells $176,778.00 in StockAcceleron Pharma (XLRN) EVP Sells $176,778.00 in Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Kevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) StockKevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Acceleron Pharma (XLRN) Lifted to Buy at ValuEngineAcceleron Pharma (XLRN) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Acceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 MillionAcceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 Million
www.americanbankingnews.com - April 1 at 2:36 AM
Acceleron Pharma (XLRN) Expected to Announce Earnings of -$0.64 Per ShareAcceleron Pharma (XLRN) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - March 30 at 5:14 PM
Oppenheimer Reaffirms "Hold" Rating for Acceleron Pharma (XLRN)Oppenheimer Reaffirms "Hold" Rating for Acceleron Pharma (XLRN)
www.americanbankingnews.com - March 30 at 12:04 PM
Acceleron Pharma (XLRN) Cut to "Hold" at BidaskClubAcceleron Pharma (XLRN) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM
Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 MillionZacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 Million
www.americanbankingnews.com - March 15 at 4:42 AM
Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 TrialAcceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
finance.yahoo.com - March 12 at 9:01 AM
Acceleron Pharma Inc (XLRN) Receives Average Rating of "Buy" from AnalystsAcceleron Pharma Inc (XLRN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 1:18 PM
Acceleron Pharma Inc (XLRN) Director Richard F. Pops Sells 37,500 SharesAcceleron Pharma Inc (XLRN) Director Richard F. Pops Sells 37,500 Shares
www.americanbankingnews.com - March 8 at 6:13 PM
Acceleron Pharma Inc (XLRN) is Sectoral Asset Management Incs 6th Largest PositionAcceleron Pharma Inc (XLRN) is Sectoral Asset Management Inc's 6th Largest Position
www.americanbankingnews.com - March 5 at 3:35 PM
Acceleron Pharma Inc (XLRN) Holdings Lifted by UBS Asset Management Americas Inc.Acceleron Pharma Inc (XLRN) Holdings Lifted by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 5 at 9:42 AM
Leerink Swann Comments on Acceleron Pharma Incs Q2 2018 Earnings (XLRN)Leerink Swann Comments on Acceleron Pharma Inc's Q2 2018 Earnings (XLRN)
www.americanbankingnews.com - March 5 at 3:12 AM
Credit Suisse Group Reiterates "Buy" Rating for Acceleron Pharma (XLRN)Credit Suisse Group Reiterates "Buy" Rating for Acceleron Pharma (XLRN)
www.americanbankingnews.com - March 2 at 9:56 PM
Acceleron Pharma Inc (XLRN) Expected to Post Q1 2018 Earnings of ($0.62) Per ShareAcceleron Pharma Inc (XLRN) Expected to Post Q1 2018 Earnings of ($0.62) Per Share
www.americanbankingnews.com - March 2 at 9:10 AM
Research Analysts Set Expectations for Acceleron Pharma Incs Q1 2018 Earnings (XLRN)Research Analysts Set Expectations for Acceleron Pharma Inc's Q1 2018 Earnings (XLRN)
www.americanbankingnews.com - March 2 at 9:10 AM
Citigroup Increases Acceleron Pharma (XLRN) Price Target to $63.00Citigroup Increases Acceleron Pharma (XLRN) Price Target to $63.00
www.americanbankingnews.com - March 1 at 5:05 PM
Acceleron Pharma Inc (XLRN) Forecasted to Earn FY2022 Earnings of ($0.07) Per ShareAcceleron Pharma Inc (XLRN) Forecasted to Earn FY2022 Earnings of ($0.07) Per Share
www.americanbankingnews.com - March 1 at 4:08 PM
Piper Jaffray Companies Boosts Acceleron Pharma (XLRN) Price Target to $53.00Piper Jaffray Companies Boosts Acceleron Pharma (XLRN) Price Target to $53.00
www.americanbankingnews.com - February 28 at 4:44 PM
Acceleron Pharmas (XLRN) Buy Rating Reiterated at HC WainwrightAcceleron Pharma's (XLRN) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - February 28 at 4:44 PM
Acceleron Pharma (XLRN) Given New $54.00 Price Target at BarclaysAcceleron Pharma (XLRN) Given New $54.00 Price Target at Barclays
www.americanbankingnews.com - February 28 at 1:40 PM
Acceleron Pharma (XLRN) Issues Quarterly  Earnings Results, Misses Estimates By $0.02 EPSAcceleron Pharma (XLRN) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - February 27 at 10:32 PM
Acceleron Pharma Inc to Host Earnings CallAcceleron Pharma Inc to Host Earnings Call
finance.yahoo.com - February 27 at 5:55 PM
Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial ResultsAcceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
finance.yahoo.com - February 27 at 5:55 PM
Hudson Bay Capital Management LP Reduces Position in Acceleron Pharma Inc (XLRN)Hudson Bay Capital Management LP Reduces Position in Acceleron Pharma Inc (XLRN)
www.americanbankingnews.com - February 27 at 2:58 PM
Acceleron Pharma (XLRN) Rating Increased to Overweight at JPMorgan Chase & Co.Acceleron Pharma (XLRN) Rating Increased to Overweight at JPMorgan Chase & Co.
www.americanbankingnews.com - February 26 at 8:46 PM
Carillon Tower Advisers Inc. Acquires Shares of 942,844 Acceleron Pharma Inc (XLRN)Carillon Tower Advisers Inc. Acquires Shares of 942,844 Acceleron Pharma Inc (XLRN)
www.americanbankingnews.com - February 26 at 12:18 PM
Acceleron Pharma Inc (XLRN) Expected to Announce Quarterly Sales of $3.39 MillionAcceleron Pharma Inc (XLRN) Expected to Announce Quarterly Sales of $3.39 Million
www.americanbankingnews.com - February 26 at 4:38 AM
Brown Advisory Inc. Grows Holdings in Acceleron Pharma Inc (XLRN)Brown Advisory Inc. Grows Holdings in Acceleron Pharma Inc (XLRN)
www.americanbankingnews.com - February 25 at 4:36 AM
Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) to Announce -$0.60 Earnings Per ShareZacks: Analysts Expect Acceleron Pharma Inc (XLRN) to Announce -$0.60 Earnings Per Share
www.americanbankingnews.com - February 24 at 3:38 PM
Citadel Advisors LLC Decreases Holdings in Acceleron Pharma Inc (XLRN)Citadel Advisors LLC Decreases Holdings in Acceleron Pharma Inc (XLRN)
www.americanbankingnews.com - February 24 at 2:21 PM
Acceleron Pharma (XLRN) Scheduled to Post Earnings on TuesdayAcceleron Pharma (XLRN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM
Acceleron Pharma (XLRN) Rating Increased to Buy at BidaskClubAcceleron Pharma (XLRN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - February 17 at 9:54 PM
Acceleron Pharma Inc (XLRN) Receives Average Recommendation of "Hold" from BrokeragesAcceleron Pharma Inc (XLRN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 11:48 AM
Acceleron Announces Appointment of Chief Commercial OfficerAcceleron Announces Appointment of Chief Commercial Officer
finance.yahoo.com - February 9 at 9:49 AM
-$0.60 EPS Expected for Acceleron Pharma Inc (XLRN) This Quarter-$0.60 EPS Expected for Acceleron Pharma Inc (XLRN) This Quarter
www.americanbankingnews.com - February 7 at 11:42 PM
Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceAcceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:37 AM
 Brokerages Anticipate Acceleron Pharma Inc (XLRN) Will Announce Quarterly Sales of $3.39 Million Brokerages Anticipate Acceleron Pharma Inc (XLRN) Will Announce Quarterly Sales of $3.39 Million
www.americanbankingnews.com - January 23 at 5:54 AM
Acceleron Pharma (XLRN) Stock Rating Reaffirmed by Credit Suisse GroupAcceleron Pharma (XLRN) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - January 21 at 5:34 PM
Acceleron Pharma Inc (XLRN) Given Average Recommendation of "Buy" by BrokeragesAcceleron Pharma Inc (XLRN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 20 at 11:48 AM
Christopher Rovaldi Sells 11,000 Shares of Acceleron Pharma Inc (XLRN) StockChristopher Rovaldi Sells 11,000 Shares of Acceleron Pharma Inc (XLRN) Stock
www.americanbankingnews.com - January 17 at 7:04 PM

SEC Filings

Acceleron Pharma (NASDAQ:XLRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acceleron Pharma (NASDAQ:XLRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acceleron Pharma (NASDAQ XLRN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.